$43.340
-1.829 (-4.22%)Al cierre
Rentabilidad y márgenes de VCYT
Evaluating the bottom line, Veracyte, Inc. maintains a gross margin of 71.93%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 15.29%, while the net margin is 16.96%. These profitability ratios, combined with a Return on Equity (ROE) of 8.77%, provide a clear picture of how effectively VCYT converts its operational activities into shareholder value.
Comparativa sectorial de VCYT
In the context of the broader market, VCYT competes directly with industry leaders such as GRAL and PLSE. With a market capitalization of $3.32B, it holds a leading position in the sector. When comparing efficiency, VCYT's gross margin of 71.93% stands against GRAL's -28.12% and PLSE's 37.10%. Such benchmarking helps identify whether Veracyte, Inc. is trading at a premium or discount relative to its financial performance.
Desempeño financiero de Veracyte Inc
Veracyte's total revenue for Q2 2026 was $150.3 million, a 15% increase year-over-year. The gross margin is strong at 71.93%, reflecting effective cost management. However, net income has shown fluctuations, with a recent net income of $25.49 million for Q2 2026.
Financials
Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.